Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Rush University Medical Center currently manages 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio shows a high degree of distribution, with 10 distinct examiners and 9 distinct art units involved in current prosecution. This breadth suggests the university is pursuing a range of pharmaceutical or biological innovations across multiple specialized patent office divisions rather than concentrating on a single niche.
The busiest examiner for the portfolio is LY, KRISTINA ELISABETH, who is responsible for 1 busiest examiner pending office action. Given that the assigned examiners are each handling a portion of the 10 pending actions, the workload is distributed across the 10 distinct examiners. This ratio between actions and examiners may lead to a variety of prosecution outcomes based on individual examiner preferences.
Practitioners should prepare for varied examination styles across the 9 distinct art units currently reviewing the center's applications. The lack of concentration in a single unit implies that the center's research output spans different technical areas. Navigating these 9 distinct art units requires a flexible strategy to address the specific trends and requirements of each different division within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (20%) |
| §103 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 6 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 1 | 37.5% | +100.0% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
| PHILIPS, BRADLEY H | 1 | 67.4% | +30.7% |
| UHLIR, CHRISTOPHER J | 1 | 61.9% | +9.7% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| COLELLO, ERIN L | 1 | 33.6% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17029113 | Focal Pressure Applicator to Cease Bleeding | COLELLO, ERIN L | 181d overdue |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | COPPINS, JANET L | 58d overdue |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | ALLEN, MARIANNE P | 20d |
| 17441029 | METHOD OF TREATING DISEASE USING A VECTOR ENCODING TPP1 | WILSON, MICHAEL C | 61d |
| 18587523 | Role of Human Pegivirus (HPGV) in Parkinson's Disease: Implications for Diagnosis and Treatment | LY, KRISTINA ELISABETH | — |
| 18550859 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH INTRANASAL NF-KAPPAB ESSENTIAL MODIFIER (NEMO)-BINDING DOMAIN (NBD) PEPTIDE | BRADLEY, CHRISTINA | — |
| 18209867 | AUTOMATIC OXYGEN TITRATION SYSTEM AND METHOD BASED ON TARGETED OXYGEN SATURATION DURING HIGH FLOW AND LOW FLOW OXYGEN THERAPY | PHILIPS, BRADLEY H | — |
| 18131849 | SYSTEM AND TECHNIQUES FOR PROVIDING CONTINUOUS AUDITORY FEEDBACK FOR PERFORMANCE-BASED ACTIVITY | UHLIR, CHRISTOPHER J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17029113 | Focal Pressure Applicator to Cease Bleeding | COLELLO, ERIN L | 181d overdue |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | COPPINS, JANET L | 58d overdue |
| 18261959 | IMPROVED TREATMENT FOR GLOBOID CELL LEUKODSYTROPHY OR KRABBE DISEASE | MOU, LIYUAN | 38d overdue |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | ALLEN, MARIANNE P | 20d |
| 17441029 | METHOD OF TREATING DISEASE USING A VECTOR ENCODING TPP1 | WILSON, MICHAEL C | 61d |
| 18587523 | Role of Human Pegivirus (HPGV) in Parkinson's Disease: Implications for Diagnosis and Treatment | LY, KRISTINA ELISABETH | — |
| 18550859 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH INTRANASAL NF-KAPPAB ESSENTIAL MODIFIER (NEMO)-BINDING DOMAIN (NBD) PEPTIDE | BRADLEY, CHRISTINA | — |
| 18209867 | AUTOMATIC OXYGEN TITRATION SYSTEM AND METHOD BASED ON TARGETED OXYGEN SATURATION DURING HIGH FLOW AND LOW FLOW OXYGEN THERAPY | PHILIPS, BRADLEY H | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1671 | 1 |
| 1654 | 1 |
| 3799 | 1 |
| 3619 | 1 |
| 1647 | 1 |
| 1638 | 1 |
| 1675 | 1 |
| 3771 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18587523 | Role of Human Pegivirus (HPGV) in Parkinson's Disease: Implications for Diagnosis and Treatment | LY, KRISTINA ELISABETH | 1671 | §101§102§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18550859 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS WITH INTRANASAL NF-KAPPAB ESSENTIAL MODIFIER (NEMO)-BINDING DOMAIN (NBD) PEPTIDE | BRADLEY, CHRISTINA | 1654 | §101§102 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18261959 | IMPROVED TREATMENT FOR GLOBOID CELL LEUKODSYTROPHY OR KRABBE DISEASE | MOU, LIYUAN | 1628 | §103DP | Final Rejection | 38d overdue | Pending | Jul 18, 2023 |
| 18209867 | AUTOMATIC OXYGEN TITRATION SYSTEM AND METHOD BASED ON TARGETED OXYGEN SATURATION DURING HIGH FLOW AND LOW FLOW OXYGEN THERAPY | PHILIPS, BRADLEY H | 3799 | §102§103§112 | Final Rejection | — | Pending | Jun 14, 2023 |
| 18131849 | SYSTEM AND TECHNIQUES FOR PROVIDING CONTINUOUS AUDITORY FEEDBACK FOR PERFORMANCE-BASED ACTIVITY | UHLIR, CHRISTOPHER J | 3619 | §103§112 | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17767620 | MODULATING INTERLEUKIN-10 SIGNALING TO BOOST HEALING IN DIABETIC WOUNDS | ALLEN, MARIANNE P | 1647 | §103§112 | Non-Final OA | 20d | Pending | Apr 08, 2022 |
| 17640698 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISORDERS | COPPINS, JANET L | 1628 | §103§112 | Non-Final OA | 58d overdue | Pending | Mar 04, 2022 |
| 17441029 | METHOD OF TREATING DISEASE USING A VECTOR ENCODING TPP1 | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | 61d | Pending | Sep 20, 2021 |
| 17258248 | Use of Immunomodulators to Control Infection and Stimulate Healing in Normal and Diabetic Wounds | BENAVIDES, JENNIFER ANN | 1675 | §103 | Final Rejection | — | Pending | Jan 06, 2021 |
| 17029113 | Focal Pressure Applicator to Cease Bleeding | COLELLO, ERIN L | 3771 | §102§103§112 | Non-Final OA | 181d overdue | Pending | Sep 23, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial